XML 32 R18.htm IDEA: XBRL DOCUMENT
v3.21.2

SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Thousands |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 02, 2021 USD ($) $ / shares shares | May 13, 2021 USD ($) | Feb. 17, 2021 USD ($) $ / shares shares | Feb. 10, 2021 USD ($) | Jul. 23, 2018 USD ($) | Oct. 19, 2017 USD ($) | Oct. 31, 2015 | Jun. 30, 2021 USD ($) agreement $ / shares shares | Jun. 30, 2020 $ / shares shares | Jun. 30, 2021 USD ($) agreement $ / shares shares | Jun. 30, 2020 $ / shares shares | Dec. 31, 2020 USD ($)
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) | shares |  |  | 8,749,999 |  |  |  |  |  |  |  |  |
Common Stock, Par or Stated Value Per Share | $ / shares |  |  |  |  |  |  |  | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 |
Gross proceeds |  |  | $ 40,200 |  |  |  |  |  |  | $ 8,575 |  |
Shares Issued, Price Per Share | $ / shares |  |  | $ 4.60 |  |  |  |  |  |  |  |  |
Convertible Debt, Current |  |  |  |  |  |  |  | $ 56,355 |  | $ 56,355 |  | $ 54,427
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares |  |  |  |  |  |  |  | 25,874,641 | 25,997,289 | 26,322,164 | 18,445,764 |
ATM Shares |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) | shares | 3,296,123 |  |  |  |  |  |  |  |  |  |  |
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.001 |  |  |  |  |  |  |  |  |  |  |
Sale of stock, maximum offering price | $ 20,000 |  |  |  |  |  |  |  |  |  |  |
Gross proceeds | $ 13,800 |  |  |  |  |  |  |  |  |  |  |
2021 Notes [Member] | Convertible Notes Payable [Member] |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Interest rate (as a percent) |  |  |  |  |  |  |  | 7.50% |  | 7.50% |  |
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member] |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage |  |  |  |  |  |  | 100.00% |  |  |  |  |
Chiesi Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue, Performance Obligation, Number | agreement |  |  |  |  |  |  |  | 2 |  | 2 |  |
Chiesi US Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Additional Amounts Payable To Cover Development Costs |  |  |  |  | $ 20,000 |  |  |  |  |  |  |
Maximum Entitlement Of Development Costs To Cover Per Year |  |  |  |  | 7,500 |  |  |  |  |  |  |
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones |  |  |  |  | $ 760,000 |  |  |  |  |  |  |
Chiesi US Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  | 15.00% |  |  |  |  |  |  |
Chiesi US Agreement [Member] | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  | 40.00% |  |  |  |  |  |  |
Chiesi Ex US Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Additional Amounts Payable To Cover Development Costs |  |  |  |  |  | $ 25,000 |  |  |  |  |  |
Maximum Entitlement Of Development Costs To Cover Per Year |  |  |  |  |  | 10,000 |  |  |  |  |  |
Agreement Amendment Payment Receivable |  | $ 10,000 |  |  |  |  |  |  |  |  |  |
Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones |  | $ 25,000 |  |  |  |  |  |  |  |  |  |
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones |  |  |  |  |  | $ 320,000 |  |  |  |  |  |
Chiesi Ex US Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  |  | 15.00% |  |  |  |  |  |
Chiesi Ex US Agreement [Member] | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  |  | 35.00% |  |  |  |  |  |
SarcoMed USA, Inc. Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
License Agreement, Initial Cash Payment |  |  |  | $ 3,500 |  |  |  |  |  |  |  |
Term to sign supply agreement |  |  |  | 60 days |  |  |  |  |  |  |  |
Chiesi US Agreement and Chiesi Ex US Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront Nonrefundable Non-Creditable Payment Receivable |  |  |  |  | $ 25,000 | $ 25,000 |  |  |  |  |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Agreement Amendment Payment Receivable + References No definition available. + Details
Name: | plx_AgreementAmendmentPaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones + References No definition available. + Details
Name: | plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of initial cash payment under the license agreement. + References No definition available. + Details
Name: | plx_LicenseAgreementInitialCashPayment
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The maximum amount payable to entity to cover development costs in any year under agreement. + References No definition available. + Details
Name: | plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Performance Obligation, Number + References No definition available. + Details
Name: | plx_RevenuePerformanceObligationNumber
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Sale of stock, maximum offering price. + References No definition available. + Details
Name: | plx_SaleOfStockMaximumOfferingPrice
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term To Sign Supply Agreement + References No definition available. + Details
Name: | plx_TermToSignSupplyAgreement
Namespace Prefix: | plx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNonCreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_ConvertibleDebtCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_SarcomedUsaInc.AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |